AstraZeneca said on Monday it has struck a deal to buy U.S.-based biopharmaceutical firm CinCor Pharma Inc for up to $1.8 billion to bolster its arsenal of heart and kidney drugs.
Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat a range of conditions including high blood pressure and chronic kidney disease.
AstraZeneca is hoping to combine baxdrostat with its own Farxiga, a diabetes drug whose sales have risen sharply after the medicine was also shown to benefit patients with heart failure as well as kidney disease.
https://finance.yahoo.com/news/1-astrazeneca-buy-u-based-073232254.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.